| 49.53 -3.15 (-5.98%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 66.5 | 1-year : | 72.41 |
| Resists | First : | 56.93 | Second : | 62 |
| Pivot price | 53.51 |
|||
| Supports | First : | 48.75 | Second : | 40.56 |
| MAs | MA(5) : | 51.54 |
MA(20) : | 53.7 |
| MA(100) : | 67.35 |
MA(250) : | 66.01  |
|
| MACD | MACD : | -2.4 |
Signal : | -2.4 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 21.6 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 104.31 | Low : | 36.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TEM ] has closed above bottom band by 11.0%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 51.96 - 52.21 | 52.21 - 52.42 |
| Low: | 48.63 - 48.97 | 48.97 - 49.24 |
| Close: | 49.08 - 49.59 | 49.59 - 50 |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Fri, 13 Mar 2026
Tempus AI, Inc. $TEM Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Thu, 12 Mar 2026
Tempus AI Inc (TEM) Shares Down 5.14% on Mar 12 - GuruFocus
Wed, 11 Mar 2026
Cathie Wood’s ARK sells LY Corp stock, buys Tempus AI - Investing.com
Wed, 11 Mar 2026
Why Tempus AI Stock Is Up Wednesday? - Benzinga
Mon, 09 Mar 2026
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 174 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 39.1 (%) |
| Held by Institutions | 54.3 (%) |
| Shares Short | 22,730 (K) |
| Shares Short P.Month | 21,400 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | -19.3 % |
| Operating Margin | -18.2 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | 83 % |
| Gross Profit (p.s.) | 4.59 |
| Sales Per Share | 7.31 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -218 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -35.15 |
| PEG Ratio | 0 |
| Price to Book value | 17.95 |
| Price to Sales | 6.77 |
| Price to Cash Flow | -39.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|